Tus-Pharmaceutical Group Co., Ltd.

000590.SZ

000590.SZTus-Pharmaceutical Group Co., Ltd.

Shenzhen

5.34

CNY

-0.08

(-1.48%)

-0.02EPS

-267.00P/E

1.28BMarket Cap

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CNE000000701

Return %

Stock

S&P500

-37.10

25.87

-39.32

25.85

-56.27

86.66

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	1.54	1.63	1.15	0.91	1.32	1.42	1.48	0.78	1.32	1.15	1.26	1.46	1.69	1.51
Basic EPS, GAAP	0.32	0.62	-0.74	-0.38	0.1	0.25	0.08	-0.16	0.18	0.09	0.15	0.08	0.11	-0.02
Free Cash Flow per Basic Share	0.04	0.02	-0.05	-0.62	-0.41	-0.22	-0.48	-0.09	-0.03	0.07	- -	0.15	-0.21	-0.09
Dividend per Share	0.02	0.09	0.2	0.02	0.01	- -	- -	0.01	0.01	- -	- -	- -	0.02	0.02
Book Value per Share	0.83	1.25	0.32	-0.07	0.03	0.28	0.42	0.25	0.43	0.52	0.67	0.75	0.85	0.75
Tangible Book Value per Share	1.02	1.55	0.55	0.13	0.07	0.38	1.79	1.85	2.04	2.12	2.29	1.7	1.94	1.85
Basic Weighted Avg Shares	223	223	223	223	223	223	233	240	240	239	239	240	240	239
Sales/Revenue/Turnover	344	363	256	203	295	317	344	186	315	275	301	351	405	361
Operating Margin (%)	26.5	12.92	-23.98	-29.36	12.1	7.81	4.82	-19.25	8.81	8.14	11.34	4.62	5.06	-2.05
Depreciation Expense	15	17	17	13	14	15	14	16	14	14	19	24	28	- -
Net Income, GAAP	72	138	-164	-86	22	55	19	-38	42	23	35	18	25	-5
Effective Tax Rate (%)	17.96	25.31	- -	- -	27.53	24.36	55.12	- -	20.59	17.8	15.29	17.09	16.14	32,666.12
Profit Margin (%)	21	37.86	-64.24	-42.23	7.59	17.38	5.58	-20.55	13.47	8.26	11.78	5.17	6.24	-1.25
Working Capital	-9	175	36	-63	-26	30	358	346	338	348	367	258	291	270
LT Debt	- -	- -	- -	- -	- -	- -	20	20	- -	9	6	95	83	85
Total Equity	361	479	270	184	206	264	583	580	622	645	682	702	728	705
Return on Invested Capital (%)	22.1	8.81	- -	- -	15.6	8.78	1.9	- -	4.12	3.31	4.9	1.92	2.2	307.61
Return on Capital (%)	33.37	52.93	- -	- -	37.89	57.91	21.93	- -	43.76	18.84	23.12	7.82	9.47	-443.36
Return on Common Equity (%)	44.03	59.05	-93.76	- -	- -	157.48	23.88	-48.42	52.41	20.01	24.84	10.69	13.21	-2.48

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	9.26%	19.64%	15.44%
Net Income, GAAP	-60.28%	-42.23%	39.41%
Free Cash Flow	-501.82%	-1,230.21%	-243.71%
Total Cash Common Dividend	128.45%	286.83%	1,139.73%
Total Equity	15.21%	4.68%	3.66%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Ms. Ting Tang
Full Time Employees: 1,237
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: No. 33, Yangliu Road Hengyang People's Republic of China 421001
IPO Date: Invalid Date
Website: www.guhan.com
Business: Tus-Pharmaceutical Group Co., Ltd. manufactures and sells traditional Chinese medicine and western medicine products. The company was formerly known as Tus-Guhan Group Corp.,Ltd. Tus-Pharmaceutical Group Co., Ltd. was founded in 1956 and is based in Hengyang, China.

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	1.54	1.63	1.15	0.91	1.32	1.42	1.48	0.78	1.32	1.15	1.26	1.46	1.69	1.51
Basic EPS, GAAP	0.32	0.62	-0.74	-0.38	0.1	0.25	0.08	-0.16	0.18	0.09	0.15	0.08	0.11	-0.02
Free Cash Flow per Basic Share	0.04	0.02	-0.05	-0.62	-0.41	-0.22	-0.48	-0.09	-0.03	0.07	- -	0.15	-0.21	-0.09
Dividend per Share	0.02	0.09	0.2	0.02	0.01	- -	- -	0.01	0.01	- -	- -	- -	0.02	0.02
Book Value per Share	0.83	1.25	0.32	-0.07	0.03	0.28	0.42	0.25	0.43	0.52	0.67	0.75	0.85	0.75
Tangible Book Value per Share	1.02	1.55	0.55	0.13	0.07	0.38	1.79	1.85	2.04	2.12	2.29	1.7	1.94	1.85
Basic Weighted Avg Shares	223	223	223	223	223	223	233	240	240	239	239	240	240	239
Sales/Revenue/Turnover	344	363	256	203	295	317	344	186	315	275	301	351	405	361
Operating Margin (%)	26.5	12.92	-23.98	-29.36	12.1	7.81	4.82	-19.25	8.81	8.14	11.34	4.62	5.06	-2.05
Depreciation Expense	15	17	17	13	14	15	14	16	14	14	19	24	28	- -
Net Income, GAAP	72	138	-164	-86	22	55	19	-38	42	23	35	18	25	-5
Effective Tax Rate (%)	17.96	25.31	- -	- -	27.53	24.36	55.12	- -	20.59	17.8	15.29	17.09	16.14	32,666.12
Profit Margin (%)	21	37.86	-64.24	-42.23	7.59	17.38	5.58	-20.55	13.47	8.26	11.78	5.17	6.24	-1.25
Working Capital	-9	175	36	-63	-26	30	358	346	338	348	367	258	291	270
LT Debt	- -	- -	- -	- -	- -	- -	20	20	- -	9	6	95	83	85
Total Equity	361	479	270	184	206	264	583	580	622	645	682	702	728	705
Return on Invested Capital (%)	22.1	8.81	- -	- -	15.6	8.78	1.9	- -	4.12	3.31	4.9	1.92	2.2	307.61
Return on Capital (%)	33.37	52.93	- -	- -	37.89	57.91	21.93	- -	43.76	18.84	23.12	7.82	9.47	-443.36
Return on Common Equity (%)	44.03	59.05	-93.76	- -	- -	157.48	23.88	-48.42	52.41	20.01	24.84	10.69	13.21	-2.48

	Dec'23	Mar'24	Jun'24
Total Current Assets	540	554	517
Accounts Receivable, Net	22	16	14
Cash, Cash Equivalents & STI	190	167	201
Inventories	130	150	148
Total Current Liabilities	249	267	247
Payables & Accruals	- -	- -	- -
ST Debt	12	37	11
Deferred Revenue	- -	- -	- -

Tus-Pharmaceutical Group Co., Ltd.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

	Dec'23	Mar'24	Jun'24
ST Debt	12	37	11
LT Borrowings	80	80	80
LT Finance Leases	3	5	5
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	239	239	239
Market Capitalization	2,145	1,786	1,262

Year	Q1	Q2	Q3	Q4	FY
2022	0.05	- -	- -	- -	0.08
2023	0.03	- -	- -	- -	0.11
2024	-0.03	- -	- -	- -	- -